TRAVERE THERAPEUTICS FACT SHEET

At Travere Therapeutics, we are in rare for life.

We come together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Who we are
Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies to people living with rare disease.

Headquartered in San Diego, CA, with operations in Europe – the company is 375+ people with a unique understanding of rare disease who cultivate a culture of compassion, integrity, and a deep-rooted commitment to people with rare disease.

We are driven by patients
Our dedication to people living with rare disease, caregivers, and advocates is a life-long commitment, and integral to who we are as an organization.

Many of our own team members are rare disease patients, survivors, and caregivers themselves. For us, advancing research, delivering life-changing therapeutics, and doing everything we can to support this community is personal. We know that time matters, and we know that the work that we do can make a difference. We know what hope looks like, but we also know what having no answer and no treatment feels like.

We are driven by science
The science we are advancing in rare kidney and metabolic disorders has the potential to set new standards of care and bring hope to the people living with these rare disorders.

HEADQUARTERS
San Diego, California
Additional offices in Dublin, Ireland, and Rapperswil-Jona, Switzerland

TEAM MEMBERS
375+ members worldwide

COMMERCIAL PORTFOLIO
Filspari® (sparsentan)
Thiola® (tiopronin), and
Thiola EC® (tiopronin, delayed-release tablets)

OUR VALUES
We are patient-inspired
We are courageous
We promote community
We are stronger together

PRIMARY AREAS OF FOCUS
Rare kidney and metabolic disorders

TRAVERE® THERAPEUTICS

Pipeline targeting rare kidney and met

1 In February 2023, the Company announced that the FDA granted approval of sparsentan under the accelerated approval pathway for the reduction of proteinuria in IgAN. In September 2023, the Company announced confirmatory data from the Phase 3 PROTECT Study of FILSPARI®. Read the press release> CSL Vifor has exclusive commercial rights for sparsentan in Europe, Australia, and New Zealand. Read the press release> Renalys Pharma has exclusive commercial rights for sparsentan in Japan, South Korea, Taiwan, and Southeast Asian nations. Read the press release>

2 In December 2023, the Company announced that following its engagement with FDA on the two-year results from the DUPLEX Study, the Company is conducting additional analyses of FSGS data, and plans to re-engage with the FDA later in 2024 following the Company's consideration of additional evidence. Read the press release>
FSGS: focal segmental glomerulosclerosis; IgAN: IgA nephropathy; HCU: classical homocystinuria; ALGS: Alagille syndrome

We are driven to deliver safe and effective therapies to patients as quickly as possible. To do this, we are advancing a pipeline of potential first-in-class medicines targeting rare diseases with significant unmet needs. Travere recently announced FDA accelerated approval of a therapy for IgA nephropathy, a rare kidney disease (RKD) that is a leading cause of kidney failure due to glomerular disease. We are in late-stage clinical development for the treatment of focal segmental glomerulosclerosis (FSGS), an RKD with no approved treatments. We are evaluating what could potentially become the first disease-modifying therapy for people living with classical homocystinuria (HCU). In partnership with the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS), and patient advocacy foundation Alagille Syndrome Alliance (ALGSA), we are engaged in preclinical research to identify and develop potentially novel therapeutics for Alagille syndrome (ALGS).

Travere Therapeutics is determined to bring life-changing treatments, support, and hope to people with rare disease – an area often overlooked. So that, together, we can create a better future for families affected by rare disease.

We are proud to be ***in rare for life***.

3611 Valley Centre Drive, Suite 300, San Diego, CA 92130
888-969-7879 | travere.com | @TravereRare

TRAVERE® THERAPEUTICS